Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: Analysis of economic data from the CLARITY study

Clinical Drug Investigation

Volumn 32, Issue 1, 2012, Pages 15-27

  Ali, Shehzad ^a   Paracha, Noman ^a   Cook, Stuart ^b   Giovannoni, Gavin ^c   Comi, Giancarlo ^d   Rammohan, Kottil ^e   Rieckmann, Peter ^f   Sørensen, Per Soelberg ^g   Vermersch, Patrick ^h   Greenberg, Steven ⁱ   Scott, David A ^a   Joyeux, Alexandre ⁱ  

^a ICON PLC   (United Kingdom)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g University of Copenhagen   (Denmark)

^h UNIV LILLE   (France)

ⁱ MERCK SERONO S A   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; PLACEBO;

ABSENTEEISM; ARTICLE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; EMERGENCY WARD; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SELF REPORT; SHORT COURSE THERAPY; TABLET; TREATMENT DURATION;

CLADRIBINE; DOUBLE-BLIND METHOD; HEALTH CARE RATIONING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; TABLETS;

EID: 82555194575     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11593310-000000000-00000     Document Type: Article

References (26)

1. National Multiple Sclerosis Society. About MS [online]. Available from URL: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know- about-ms/who-getsms/index.aspx [Accessed 2010 Dec 9]
2. Multiple Sclerosis International Federation. Atlas of MS [online]. Available from URL: http://www.atlasofms.org [Accessed 2010 Dec 9]
3. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000 Sep; 343 (13): 938-52
4. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007; 79: 43-72
5. McDole J, Johnson AJ, Pirko I. The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res 2006 Apr; 28 (3): 256-61 (Pubitemid 43765109)
6. Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol 2008 Sep; 7 (9): 852-8
7. Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol 2005; 23: 683-747 (Pubitemid 40563183)
8. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003 Dec; 61 (11): 1528-32 (Pubitemid 37505574)
9. Forbes A, While A, Mathes L, et al. Health problems and health-related quality of life in people with multiple sclerosis. Clin Rehabil 2006 Jan; 20 (1): 67-78 (Pubitemid 43246334)
10. Amato MP. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. Expert Opin Pharmacother 2004 Oct; 5 (10): 2115-26 (Pubitemid 39406113)
11. OBrien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003 Sep; 3 (1): 17
12. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006 Aug; 77 (8): 918-26 (Pubitemid 44174075)
13. Kobelt G. Health economic issues in MS. IntMS J 2006 Jan; 13 (1): 17-26, 16
14. Earnshaw SR, Graham J, Oleen-BurkeyM, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsingremitting multiple sclerosis. Appl Health Econ Health Policy 2009; 7 (2): 91-108
15. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992 Oct; 340 (8825): 952-6
16. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983 Oct; 62 (4): 737-43 (Pubitemid 13008659)
17. Guarnaccia JB, Rinder H, Smith B. Preferential depletion of lymphocyte subpopulations by cladribine in a phase III clinical trial in multiple sclerosis [poster P55]. World Congress on Treatment and Research in Multiple Sclerosis [WCTRIMS], Montreal, 17-20 Sep 2008
18. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007 Nov; 23 (11): 2667-76 (Pubitemid 350146405)
19. Soelberg Sørensen P, Comi G, Cook S, et al. Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, phase III, double-blind, placebo-controlled CLARITY study (Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Dusseldorf, Germany, 9-12 Sep 2009) [abstract P472]. Mult Scler 2009; 15 (Suppl. 2): S137
20. Salvat C, Curchod M-L, Guedj E, et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis (Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Dusseldorf, Germany, 9-12 Sep 2009) [abstract P280]. Mult Scler 2009; 15 (Suppl. 2): S74-5
21. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 Jan; 362 (5): 416-26
22. Canadian Institute for Health Information. DAD resource intensity weights and expected lengths of stay for CMG+. Report. Ottawa (ON), 2009
23. Public Health Agency of Canada (PHAC). Exploring the link between work-life conflict and demands on Canadas health care system. Appendix E. Report 3, March 2004
24. Ontario Ministry of Health and Long Term Care. Ontario Health Insurance Program (OHIP) Schedule of Benefits and Fees (Physicians) 2009 [online]. Available from URL: http://www.health.gov.on.ca/english/providers/program/ohip/ sob/sob-mn.html [Accessed 2011 Sep 1]
25. Statistics Canada: Prices Division. The consumer price index: report. Feb 2009 [online]. Available from URL: http://www.statcan.gc.ca [Accessed 2011 Sep 1]
26. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011; 17 (5): 578-93